Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report.
Int Immunopharmacol
; 125(Pt A): 111137, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-37897946
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dermatitis, Atopic
Limits:
Humans
Language:
En
Journal:
Int Immunopharmacol
Journal subject:
ALERGIA E IMUNOLOGIA
/
FARMACOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: